Effect of testosterone formulations on hematocrit in transgender individuals: A systematic review
Andrology · 2025-03 · 13 (3) · 422-430
DOI: 10.1111/andr.13695 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Andrology, online erschienen am 16.07.2024. Verfasst von Sérgio Henrique Pires Okano und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology and Obstetrics, University of São Paulo, Ribeirão Preto, Brazil. Hauptthemen laut MEDLINE: Polycythemia, Testosterone, Transgender Persons. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 34 Literaturangaben.
Abstract (Originalsprache)
Background
Approximately, 11% of trans men experience erythrocytosis diagnosis due to testosterone administration during the first year of the gender‐affirming hormone treatment (GAHT).
Objectives
To identify and compare the effect of different testosterone formulations on hematocrit (Hct) and diagnose erythrocytosis in trans men. Materials and methods This systematic review was based on PRISMA guidelines. We performed an electronic search of PubMed, Embase, and Web of Science in January 2024. The Newcastle–Ottawa scale was used to evaluate the quality of evidence in the observational studies.
Results
Of the 152 records retrieved, 18 met the eligibility criteria. Studies observed an increase of up to 5% in Hct in trans men using injectable testosterone undecanoate (TU), and up to 6.9% in trans men using intermediate injectable testosterone esters (TE). Trans men using TE experience a larger increase in serum Hct levels compared to those receiving TU. Erythrocytosis prevalence varies according to the cutoff used (50%, 52%, and 54%). Erythrocytosis was also associated with tobacco use, age at initiation of hormone therapy, body mass index (BMI), and pulmonary conditions. Studies that evaluated the effect of testosterone formulation on erythrocytosis diagnosis present conflicting result. Trans men have a hazard ratio of 7.4 (95% CI: 4.1, 13.4) of developing erythrocytosis compared to cisgender men, using a 52% hematocrit cutoff.
Conclusion
All testosterone formulations result in an increase in Hct, irrespective of dose, formulation, and administration method. Smoking, higher age at initiation of the testosterone therapy, higher BMI, and a predisposing medical history are associated with this increase in Hct. The difference in effect of TE and TU on Hct is conflicting, although it is important to point out that these data come from observational studies, retrospective, and with a small‐sample size.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology and Obstetrics, University of São Paulo, Ribeirão Preto, Brazil.
- Department of Social Medicine, University of São Paulo, Ribeirão Preto, Brazil.
- Department of Gynecology and Obstetrics, University of Campinas, Campinas, Brazil.
ORCID-Profile: Sérgio Henrique Pires Okano
Zitieren
APA
Okano, S. H. P., Braga, G. C., Cantelli, D. A. L., Filho, L. A. S. P., Brito, L. G. O., & Lara, L. A. D. S. (2025). Effect of testosterone formulations on hematocrit in transgender individuals: A systematic review. Andrology, 13(3), 422-430. https://doi.org/10.1111/andr.13695
Vancouver
Okano SHP, Braga GC, Cantelli DAL, Filho LASP, Brito LGO, Lara LADS. Effect of testosterone formulations on hematocrit in transgender individuals: A systematic review. Andrology. 2025;13(3):422-430. doi:10.1111/andr.13695
BibTeX
@article{Okano2025,
author = {Okano, Sérgio Henrique Pires and Braga, Giordana Campos and Cantelli, Débora Aiesha Leite and Filho, Luis Antônio S Pires and Brito, Luiz Gustavo Oliveira and Lara, Lucia Alves da Silva},
title = {Effect of testosterone formulations on hematocrit in transgender individuals: A systematic review},
journal = {Andrology},
year = {2025},
volume = {13},
number = {3},
pages = {422--430},
doi = {10.1111/andr.13695}
}
EUVIMED